Adaptive Biotechnologies ADPT Immune Medicine Business — Segment Reporting Other Item Amount
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's immune medicine business — segment reporting other item amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's immune medicine business — segment reporting other item amount?
- Adaptive Biotechnologies (ADPT) reported immune medicine business — segment reporting other item amount of $5.78M in Q1 2026.
- How has Adaptive Biotechnologies's immune medicine business — segment reporting other item amount changed year-over-year?
- Adaptive Biotechnologies's immune medicine business — segment reporting other item amount increased by 12.1% year-over-year, from $5.15M to $5.78M.
- What is the long-term trend for Adaptive Biotechnologies's immune medicine business — segment reporting other item amount?
- Over 3 years (2022 to 2025), Adaptive Biotechnologies's immune medicine business — segment reporting other item amount has grown at a -32.7% compound annual growth rate (CAGR), from $70.02M to $21.38M.
- What does immune medicine business — segment reporting other item amount mean?
- This metric captures miscellaneous expenses or income items specific to the Immune Medicine Business segment that do not fall into standard operating categories. It provides transparency into non-recurring or unique operational costs that impact the segment's overall financial performance.